You might also like
Insulet Corporation, headquartered in Massachusetts, is a medical device company focused on developing, manufacturing, and selling continuous insulin delivery systems for individuals with insulin-dependent diabetes. The company's primary product line is the Omnipod platform, which includes the Omnipod Insulin Management System, Omnipod DASH, and Omnipod 5 Automated Insulin Delivery System, all featuring a tubeless, wearable design for up to three days of continuous insulin delivery controlled via a smartphone or dedicated controller . Insulet also engages in the sale of a modified version of the Pod for drug delivery to pharmaceutical and biotechnology companies, and is expanding its offerings to include non-insulin subcutaneous drug delivery across other therapeutic areas .
- Omnipod Platform - Develops and sells a range of continuous insulin delivery systems, including the Omnipod Insulin Management System, Omnipod DASH, and Omnipod 5 Automated Insulin Delivery System, all designed for tubeless, wearable insulin delivery.
- Drug Delivery - Provides a modified version of the Pod to pharmaceutical and biotechnology companies for drug delivery applications.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
James R. Hollingshead ExecutiveBoard | President and Chief Executive Officer | None | Joined Insulet as CEO in June 2022 after serving on the Board since July 2019. Former President of ResMed's Sleep and Respiratory Care business. Holds a Ph.D. in Political Science. | View Report → |
Ana Maria Chadwick Executive | EVP, Chief Financial Officer and Treasurer | Board Member at Dollar General and LiveGirl | Joined Insulet in April 2024. Former CFO at Pitney Bowes and GE executive. Holds a B.A. in Economics and Business Administration. | |
Dan Manea Executive | SVP, Chief Human Resources Officer | None | Joined Insulet in May 2020. Former HR leader at Novartis and Eli Lilly. Holds an MBA and is a certified medical doctor. | |
Eric Benjamin Executive | EVP, Chief Product and Customer Experience Officer | None | Joined Insulet in May 2015. Held multiple leadership roles, including EVP of Innovation and Strategy. Key contributor to the Omnipod\u00ae 5 launch. Holds an MBA from Harvard Business School. | |
John Kapples Executive | SVP, General Counsel | None | Joined Insulet in March 2019. Former VP and General Counsel at GCP Applied Technologies. Extensive legal experience at Medtronic, Covidien, and Raytheon. Holds a J.D. from Georgetown University. | |
Laetitia Cousin Executive | SVP, Regulatory Affairs, Quality Assurance, and Compliance | None | Joined Insulet in 2022. Over 25 years of experience in regulatory and quality roles. Former leader at SeaSpine Holdings and NuVasive. Holds a B.S. in Biological Sciences. | |
Lauren Budden Executive | Interim Chief Financial Officer and Treasurer; Group VP, Chief Accounting Officer, and Controller | None | Joined Insulet in April 2019. Promoted to Group VP in March 2022. Assumed Interim CFO role in October 2023. Former VP at Gulf Oil and Medtronic. CPA with an MBA from UMass Amherst. | |
Prem Singh Executive | SVP, Global Operations | None | Joined Insulet in 2021. Former VP at Thermo Fisher Scientific and GE. Certified Six Sigma Master Black Belt. | |
Elizabeth H. Weatherman Board | Board Member | Special Limited Partner at Warburg Pincus; Board Member at Nevro, Silk Road Medical, and Vapotherm; Trustee at Stanford and Mount Holyoke | Joined Insulet's Board in February 2022. Former leader at Warburg Pincus. Extensive experience in healthcare investments. | |
Flavia H. Pease Board | Board Member | EVP and CFO at Charles River Laboratories | Joined Insulet's Board in January 2024. Former VP at Johnson & Johnson. Extensive financial leadership experience. | |
Luciana Borio Board | Board Member | Venture Partner at ARCH Venture Partners; Board Member at Eagle Pharmaceuticals; Adjunct Faculty at Johns Hopkins; Senior Fellow at CFR | Joined Insulet's Board in October 2021. Physician and global health expert. Former FDA official. | |
Michael R. Minogue Board | Board Member | President and CEO of Minogue Consulting and Heartwork Capital; Board Member at MedTechVets | Joined Insulet's Board in August 2017. Former Chairman and CEO of Abiomed. Holds three patents. | |
Timothy C. Stonesifer Board | Board Member | CFO at Alcon Inc. | Joined Insulet's Board in January 2024. Former CFO at Hewlett-Packard Enterprise and GE. Holds a B.A. in Economics from the University of Michigan. | |
Timothy J. Scannell Board | Chairman of the Board | Board Member at Exact Sciences and NovoCure | Joined Insulet's Board in 2014. Former President and COO of Stryker Corporation. Holds an MBA from the University of Notre Dame. | |
Wayne A.I. Frederick Board | Board Member | Board Member at Humana, Workday, and Agostini's Limited; Charles R. Drew Professor at Howard University | Joined Insulet's Board in October 2020. Former President of Howard University. Renowned surgeon and researcher. |
-
Given that over 85% of your U.S. new customer starts came from people previously on multiple daily injections (MDI), how do you plan to sustain this growth trajectory, and what strategies are in place to continue converting MDI users to Omnipod therapy in a market that may become increasingly saturated?
-
With competitors entering the pharmacy channel and pushing on pricing, how confident are you in your ability to defend your pricing and margins in this channel, and what measures are you taking to mitigate potential pricing pressures from these competitors?
-
You mentioned that retention rates among type 2 patients might be lower due to comorbidities and other factors; how do you plan to address potential retention challenges in the type 2 segment to ensure sustained growth and customer loyalty?
-
As you expand internationally, particularly in Europe where patients are on longer contract cycles, what challenges do you anticipate in accelerating the adoption of Omnipod 5, and how will these contract structures impact your growth strategy and market penetration in these markets?
-
While your customer service has scaled since the overwhelming demand at the launch of Omnipod 5, how are you ensuring that service quality remains high as you continue to grow rapidly, and what steps are you taking to prevent service issues from impacting patient satisfaction and retention?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
This company is a major player in the tubed insulin pump market and has historically held the majority share of this segment. It is also a large, well-capitalized company with significant resources, including greater name recognition, established relationships with healthcare professionals, and a more extensive distribution network. | |
This company is a competitor in the insulin pump market, specifically in the tubed pump segment. | |
The Ypsomed Group | This company is mentioned as a competitor in the insulin pump market. |
Roche Diabetes Care, Inc. | This company is a competitor in the insulin pump market and is noted as a large, well-capitalized company with significant resources. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Distributor A | Major distributor of Omnipod products | All | 28% of total revenue in 2024 and 2023, and 19% in 2022. Represents 35% of total net accounts receivable trade as of December 31, 2024. |
Distributor B | Major distributor of Omnipod products | All | 26% of total revenue in 2024, 24% in 2023, and 16% in 2022. Represents 27% of total net accounts receivable trade as of December 31, 2024. |
Distributor C | Major distributor of Omnipod products | All | 21% of total revenue in 2024, 19% in 2023, and 17% in 2022. Represents 15% of total net accounts receivable trade as of December 31, 2024. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Bigfoot Biomedical, Inc. | 2023 | Insulet acquired approximately 400 patents and numerous global patent applications covering pump-based automated insulin delivery technologies for $25.1 million, with the acquired patent assets having an 11-year useful life; this strategic move enhances Insulet's IP portfolio in diabetes care. |
Dynalloy, Inc. | 2022 | The acquisition involved substantially all assets related to SMA wire assemblies used in Omnipods production for $29.0 million (with $26.0 million paid in cash at closing and $3.0 million held back for adjustments); the deal, including detailed fair value allocations and anticipated cost savings from supplier integration, strategically reinforces Insulet's manufacturing capabilities. |
Recent press releases and 8-K filings for PODD.
- Strong Q1 Performance: Revenue reached $569 million, marking approximately 30% year-over-year growth with robust margins (71.9% ; 69.8% gross and 14.9% operating ; ).
- Raised Guidance: Updated Q2 and FY 2025 outlook with revenue growth expected at 19%-22%, including U.S. Omnipod growth of 18%-21% and International Omnipod growth of 27%-30% (, ).
- Strategic & Financial Moves: Expanded the sales force and type 2 diabetes market penetration; executed a $450 million note issuance and initiated a $125 million share repurchase program (, ).
- Milestone Achievement: Attained a $2.1B 2024 revenue target and celebrated its 9th consecutive year of solid growth while reinforcing its status as the #1 provider in the U.S. for new customer starts and pump usage ().
- Global Market Strength: Delivered robust performance across both U.S. and international markets, overcoming tariff pressures (, ).
- Ashley McEvoy has been appointed President and CEO, effective April 28, 2025, and will join the Board, succeeding Jim Hollingshead.
- Former CEO Jim Hollingshead’s employment has ceased and he will serve in a consulting role to ensure a smooth transition.
- The company expects to exceed its Q1 revenue guidance and plans to raise full-year guidance.
- RADIANT trial data showed a 0.8% A1c reduction and a 22% time-in-range improvement (reaching 66%) in type 1 patients using Omnipod 5 with the FreeStyle Libre 2 sensor, supporting the efficacy of their AID system.
- Strong real-world impacts were noted in both type 1 and type 2 populations, with discussions on increased AID adoption in the U.K. and the U.S., despite challenges such as reimbursement and clinic capacity constraints.
- Upcoming studies including a next-generation SmartAdjust 2.0 update and EVOLUTION feasibility studies are in the pipeline to advance full closed-loop technology, aiming to simplify diabetes management without pre-meal bolusing, although timing remains undisclosed.
- Form 8-K Filed: Insulet Corporation filed a Form 8-K on March 21, 2025, disclosing updated material contractual and financial information.
- Securities Listing: The filing confirms that the company’s common stock, trading under the ticker PODD on NASDAQ, remains active.
- Key Disclosures: The document details complex legal provisions including note redemption procedures, asset disposition definitions, and various non-recurring financial and restructuring expense items that could affect the company’s financial obligations.
- Insulet Corp proposes issuing $450 million in senior unsecured notes due 2033 via a private placement, aiming to finance the redemption of Convertible Senior Notes and cover other corporate needs.
- The company also plans to amend its Credit Agreement to extend its revolving credit facility maturity from 2028 to 2030 and boost credit commitments by $200 million, reaching total commitments of up to $500 million.
- Both initiatives are subject to market conditions and may not proceed as initially described.
- Mark Field, Senior Vice President and Chief Technology Officer, has departed the company effective March 14, 2025, to pursue other opportunities.
- Amit Guliani, currently Group Vice President, Software Engineering, has been appointed as acting Chief Technology Officer, with Mark Field set to receive standard severance and potentially enter into a consulting agreement to aid the transition.
- Insulet Corporation entered into a material definitive 2025 Addendum to its existing Purchase Agreement with NXP USA, Inc., extending and amending key terms effective January 1, 2025.
- The addendum amends pricing, volume, warranties, and product modification terms, and confirms that orders have been placed for Q1 and Q2 2025.
- The document, filed as an 8-K, includes execution details and signatures from both parties, confirming the updates to the long-standing agreement.